z-logo
Premium
Effect of linear polarized near‐infrared ray irradiation on the chemiluminescence of human neutrophils and serum opsonic activity
Author(s) -
Shiraishi Masahiko,
Suzuki Katsuhiko,
Nakaji Shigeyuki,
Sugawara Kazuo,
Sugita Naoto,
Suzuki KohJun,
Ohta Seikou
Publication year - 1999
Publication title -
luminescence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 45
eISSN - 1522-7243
pISSN - 1522-7235
DOI - 10.1002/(sici)1522-7243(199909/10)14:5<239::aid-bio533>3.0.co;2-n
Subject(s) - chemiluminescence , opsonin , luminol , lucigenin , superoxide , chemistry , reactive oxygen species , irradiation , antibody opsonization , phagocytosis , photochemistry , in vitro , biochemistry , immunology , biology , enzyme , chromatography , physics , nuclear physics
The purpose of this study was to investigate the in vitro effects of linear polarized near‐infrared ray irradiation on neutrophil chemiluminescence (CL) and serum opsonic activity. We used luminol‐ and lucigenin‐dependent CL to detect the affected reactive oxygen species production process of human neutrophils and measured serum opsonic activity based on luminol‐dependent CL. The linear polarized near‐infrared ray irradiation suppressed a maximum light emission (peak height) of luminol‐ and lucigenin‐dependent CL in a dose‐dependent manner. The findings suggested that the linear polarized near‐infrared ray irradiation suppressed the superoxide anion and hypochlorite production of human neutrophils. The serum opsonic activity was decreased by linear polarized near‐infrared ray irradiation, and this suppressive effect might be caused by inhibiting the activation of the classical and alternative complement pathway. Therefore, it is suggested that near‐infrared ray irradiation may have an inhibitory effect against chronic pain via reduction of reactive oxygen species production and opsonic activity. Copyright © 1999 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here